Combination or improved versions of approved products

Pharma Two B is focused on developing innovative combination therapies aimed at improving the quality of life for patients with Parkinson's disease. Their lead product, P2B001, is a once-daily oral capsule that combines two previously approved medications: pramipexole, a dopamine agonist, and rasagiline, a MAO-B inhibitor. This combination is designed to optimize treatment efficacy while minimizing side effects, as evidenced by clinical studies demonstrating its effectiveness in managing motor symptoms and daily functioning in early-stage Parkinson's patients. The formulation allows for a lower dose of each component, which contributes to a favorable safety profile.

The clinical evidence supporting P2B001 includes a Phase III study that compared its efficacy against its individual components and a marketed pramipexole formulation. Results indicated that P2B001 not only improved motor symptoms significantly but also did so with fewer dopaminergic side effects and reduced daytime sleepiness compared to higher doses of pramipexole. The study enrolled 544 treatment-naïve patients across multiple centers in the US, Europe, and Canada, showcasing the product's potential as a superior treatment option for early Parkinson's disease. Overall, Pharma Two B's approach emphasizes the development of combination products that leverage existing therapies to enhance patient outcomes.

Israel

Pharma Two B is a clinical-stage pharmaceutical company developing novel, synergistic, combination products based on previously approved drugs. We refined our years of expertise to identify and characterize potential drug combinations that can offer high therapeutic effects with improved safety profiles. Our goal is to develop clinically meaningful and safe added-value combination products to address unmet medical needs. Our lead investigational product, P2B001, successfully completed both Phase IIb and Phase III studies for the treatment for early Parkinson’s Disease (PD).

Pharma Two B

Company Details